MX363306B - Derivados del acido de meldrum, acido barbiturico y pirazolona sustituidos con hidroxilamina como donadores de nitroxilo (hno). - Google Patents

Derivados del acido de meldrum, acido barbiturico y pirazolona sustituidos con hidroxilamina como donadores de nitroxilo (hno).

Info

Publication number
MX363306B
MX363306B MX2014004596A MX2014004596A MX363306B MX 363306 B MX363306 B MX 363306B MX 2014004596 A MX2014004596 A MX 2014004596A MX 2014004596 A MX2014004596 A MX 2014004596A MX 363306 B MX363306 B MX 363306B
Authority
MX
Mexico
Prior art keywords
acid
compounds
meldrum
hydroxylamine
pharmaceutical compositions
Prior art date
Application number
MX2014004596A
Other languages
English (en)
Spanish (es)
Other versions
MX2014004596A (es
Inventor
p toscano John
a guthrie Daryl
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2014004596A publication Critical patent/MX2014004596A/es
Publication of MX363306B publication Critical patent/MX363306B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • C07D231/22One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • C07D239/62Barbituric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/061,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2014004596A 2011-10-17 2012-10-16 Derivados del acido de meldrum, acido barbiturico y pirazolona sustituidos con hidroxilamina como donadores de nitroxilo (hno). MX363306B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548036P 2011-10-17 2011-10-17
PCT/US2012/060425 WO2013059194A1 (en) 2011-10-17 2012-10-16 Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors

Publications (2)

Publication Number Publication Date
MX2014004596A MX2014004596A (es) 2014-09-04
MX363306B true MX363306B (es) 2019-03-20

Family

ID=47143299

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004596A MX363306B (es) 2011-10-17 2012-10-16 Derivados del acido de meldrum, acido barbiturico y pirazolona sustituidos con hidroxilamina como donadores de nitroxilo (hno).

Country Status (13)

Country Link
US (3) US9181213B2 (cg-RX-API-DMAC7.html)
EP (1) EP2776402B1 (cg-RX-API-DMAC7.html)
JP (1) JP6177246B2 (cg-RX-API-DMAC7.html)
KR (1) KR102061537B1 (cg-RX-API-DMAC7.html)
CN (2) CN108409662B (cg-RX-API-DMAC7.html)
AU (2) AU2013201929B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014009282B1 (cg-RX-API-DMAC7.html)
CA (1) CA2852914C (cg-RX-API-DMAC7.html)
HK (1) HK1200168A1 (cg-RX-API-DMAC7.html)
IL (1) IL232101A (cg-RX-API-DMAC7.html)
MX (1) MX363306B (cg-RX-API-DMAC7.html)
SG (1) SG11201401587QA (cg-RX-API-DMAC7.html)
WO (1) WO2013059194A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2776402B1 (en) 2011-10-17 2017-07-26 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
EP3427728B1 (en) 2013-01-18 2021-07-07 Cardioxyl Pharmaceuticals, Inc. Pharmaceutical compositions comprising nitroxyl donors
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2015183839A1 (en) 2014-05-27 2015-12-03 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
EP3148983A1 (en) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
EP3313831B1 (en) 2015-06-26 2021-03-10 The Johns Hopkins University N-substituted hydroxamic acids with carbon-based leaving groups as efficient hno donors and uses thereof
EP3365325A1 (en) 2015-10-19 2018-08-29 Cardioxyl Pharmaceuticals Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
EP3365328A1 (en) 2015-10-19 2018-08-29 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US10913728B2 (en) 2016-07-28 2021-02-09 The Johns Hopkins University O-substituted hydroxamic acids
SG11201906145YA (en) 2017-01-03 2019-08-27 Cardioxyl Pharmaceuticals Inc Method of administering nitroxyl donating compounds
RS63124B1 (sr) 2018-03-08 2022-05-31 Incyte Corp Aminopirazin diol jedinjenja kao pi3k-y inhibitori
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US11912647B2 (en) 2020-05-22 2024-02-27 University Of Georgia Research Foundation, Inc. Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
EP0188040B1 (en) 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
EP1026162A4 (en) 1997-10-24 2001-01-17 Shionogi & Co ANTI-RHUMATISMAL AGENT
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
DE69924735T2 (de) 1998-07-28 2006-01-19 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) * 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
AU2005209843B2 (en) 2004-01-30 2012-02-16 The Johns Hopkins University Nitroxyl progenitor compounds and methods of use
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2007002444A1 (en) 2005-06-23 2007-01-04 Johns Hopkins University Thiol-sensitive positive inotropes
EP2596785A1 (en) * 2006-03-17 2013-05-29 Johns Hopkins University School of Medicine N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
CA2648384A1 (en) 2006-04-13 2007-10-25 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
BRPI0817562A2 (pt) 2007-09-26 2017-05-02 Cardioxyl Pharmaceuticals Inc derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
HUE030372T2 (en) 2008-05-07 2017-05-29 Cardioxyl Pharmaceuticals Inc New nitroso compounds as nitroxyl donors and methods for their use
US20110160200A1 (en) 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
CN105130855B (zh) * 2009-12-07 2018-05-25 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物及其用途
JP5826762B2 (ja) 2009-12-07 2015-12-02 ザ ジョンズ ホプキンス ユニバーシティ N−アシルオキシスルホンアミドおよびn−ヒドロキシ−n−アシルスルホンアミド誘導体
EP2776402B1 (en) 2011-10-17 2017-07-26 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
EP3427728B1 (en) 2013-01-18 2021-07-07 Cardioxyl Pharmaceuticals, Inc. Pharmaceutical compositions comprising nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2015183839A1 (en) 2014-05-27 2015-12-03 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
EP3148983A1 (en) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors

Also Published As

Publication number Publication date
US20140275134A1 (en) 2014-09-18
MX2014004596A (es) 2014-09-04
CN104053647A (zh) 2014-09-17
US9499511B2 (en) 2016-11-22
AU2013201929B2 (en) 2015-07-23
IL232101A (en) 2017-04-30
SG11201401587QA (en) 2014-07-30
US20170050947A1 (en) 2017-02-23
CA2852914C (en) 2019-11-26
BR112014009282B1 (pt) 2021-12-14
CN104053647B (zh) 2018-06-01
HK1200168A1 (en) 2015-07-31
KR102061537B1 (ko) 2020-01-03
EP2776402A1 (en) 2014-09-17
EP2776402B1 (en) 2017-07-26
US9181213B2 (en) 2015-11-10
WO2013059194A1 (en) 2013-04-25
IL232101A0 (en) 2014-05-28
CN108409662A (zh) 2018-08-17
BR112014009282A2 (pt) 2017-06-13
AU2015246114A1 (en) 2015-11-12
KR20140107197A (ko) 2014-09-04
US9862699B2 (en) 2018-01-09
BR112014009282A8 (pt) 2020-04-22
JP6177246B2 (ja) 2017-08-09
CN108409662B (zh) 2021-10-26
JP2015501308A (ja) 2015-01-15
AU2013201929A1 (en) 2013-05-02
US20160115148A1 (en) 2016-04-28
CA2852914A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
MX363306B (es) Derivados del acido de meldrum, acido barbiturico y pirazolona sustituidos con hidroxilamina como donadores de nitroxilo (hno).
IN2012DN05025A (cg-RX-API-DMAC7.html)
MX356796B (es) Derivados de hidroxilamina bis-acilados.
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
EA201171216A1 (ru) Фенилацетат l-орнитина и способы его получения
HK1215256A1 (zh) 用作吲哚胺2,3-二氧化酶的抑制劑的化合物
MX366426B (es) Compuestos de heterociclilo como inhibidores de mek.
EA201490696A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh
WO2014014835A8 (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EA201000098A1 (ru) Производные хиназолинамида
WO2012066578A3 (en) Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
EA201491866A1 (ru) Способ обработки волос
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
EA023861B3 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
ATE538100T1 (de) Aminotetrahydroindazoloessigsäuren
HK1211947A1 (en) Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors
TN2017000458A1 (en) Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors
PH12013500545A1 (en) Oxadiazole inhibitors of leukotriene production
Ichikawa et al. Discovery of atrop fixed alkoxy-aminobenzhydrol derivatives: novel, highly potent and orally efficacious squalene synthase inhibitors
CN104119282B (zh) 一种嘧菌酯的脱色和提纯方法
WO2013048989A3 (en) Pyrazole compounds
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase
EA201300408A1 (ru) Производные фенилхиназолина